Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO0GJ1
|
|||
| Drug Name |
LKA651
|
|||
| Synonyms |
9-Nov
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 2 | [1] | |
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erythropoietin (EPO) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| HIF-1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Signaling events mediated by Stem cell factor receptor (c-Kit) | ||||
| EPO signaling pathway | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | |||
| WikiPathways | EPO Receptor Signaling | |||
| Hematopoietic Stem Cell Differentiation | ||||
| Differentiation Pathway | ||||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03927690) Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Novartis. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.